ATE235482T1 - Isocumarinderivate und deren verwendung in medikamenten - Google Patents

Isocumarinderivate und deren verwendung in medikamenten

Info

Publication number
ATE235482T1
ATE235482T1 AT96917702T AT96917702T ATE235482T1 AT E235482 T1 ATE235482 T1 AT E235482T1 AT 96917702 T AT96917702 T AT 96917702T AT 96917702 T AT96917702 T AT 96917702T AT E235482 T1 ATE235482 T1 AT E235482T1
Authority
AT
Austria
Prior art keywords
isocumarine
medications
derivatives
pharmaceutical preparations
vascularization
Prior art date
Application number
AT96917702T
Other languages
English (en)
Inventor
Shin-Ichi Hirano
Toshiyuki Mase
Naoki Agata
Hiroshi Iguchi
Naoki Matsumoto
Takeo Yoshioka
Hiroshi Tone
Hiroyuki Kumagai
Masaaki Ishizuka
Tomio Takeuchi
Original Assignee
Mercian Corp
Zaidan Hojin Biseibutsu
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Mercian Corp, Zaidan Hojin Biseibutsu filed Critical Mercian Corp
Application granted granted Critical
Publication of ATE235482T1 publication Critical patent/ATE235482T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
    • C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D311/76—Benzo[c]pyrans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Rheumatology (AREA)
  • Transplantation (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Cardiology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyrane Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
AT96917702T 1994-12-19 1996-06-17 Isocumarinderivate und deren verwendung in medikamenten ATE235482T1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP6333769A JPH08176138A (ja) 1994-12-19 1994-12-19 イソクマリン誘導体
PCT/JP1996/001657 WO1997048693A1 (en) 1994-12-19 1996-06-17 Isocoumarin derivatives and use thereof in drugs
CA002259621A CA2259621C (en) 1994-12-19 1996-06-17 Isocoumarin derivatives and their use in medicines

Publications (1)

Publication Number Publication Date
ATE235482T1 true ATE235482T1 (de) 2003-04-15

Family

ID=27170918

Family Applications (1)

Application Number Title Priority Date Filing Date
AT96917702T ATE235482T1 (de) 1994-12-19 1996-06-17 Isocumarinderivate und deren verwendung in medikamenten

Country Status (9)

Country Link
US (1) US6020363A (de)
EP (1) EP0930310B1 (de)
JP (2) JPH08176138A (de)
AT (1) ATE235482T1 (de)
AU (1) AU6017296A (de)
CA (1) CA2259621C (de)
DE (1) DE69627042T2 (de)
ES (1) ES2190469T3 (de)
WO (1) WO1997048693A1 (de)

Families Citing this family (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20010001270A (ko) 1999-06-03 2001-01-05 복성해 혈관신생을 억제하는 새로운 이소쿠마린 유도체
AU5571900A (en) * 1999-07-22 2001-02-13 Mercian Corporation Process for producing isocoumarins and intermediates for the same
JP2001122870A (ja) * 1999-10-27 2001-05-08 Mercian Corp イソクマリン誘導体およびそれらの製造方法
US6473960B1 (en) 2000-01-07 2002-11-05 Storage Technology Corporation Method of making nitrided active elements
US6589981B2 (en) * 2000-02-29 2003-07-08 Ilex Oncology, Inc. Tumor radiosensitization and/or chemopotentiation using isocoumarin derivatives
US6900239B2 (en) * 2000-02-29 2005-05-31 Ilwz Ilex Products, Inc. Tumor chemopotentiation using isocoumarin derivatives
US20040018181A1 (en) * 2000-09-11 2004-01-29 KUFE Donald W. MUC1 interference RNA compositions and methods derived therefrom
JP5165175B2 (ja) * 2000-09-11 2013-03-21 デイナ ファーバー キャンサー インスティチュート，インコーポレイテッド Ｍｕｃ１細胞外ドメインおよびそれから得られた癌治療組成物
AU9598601A (en) 2000-10-20 2002-04-29 Eisai Co Ltd Nitrogenous aromatic ring compounds
US20040166248A1 (en) * 2000-12-15 2004-08-26 Sheng-Hsin Hu Coated activated carbon
US6740406B2 (en) 2000-12-15 2004-05-25 Kimberly-Clark Worldwide, Inc. Coated activated carbon
EP1531842A4 (de) * 2000-12-22 2007-03-07 Dana Farber Cancer Inst Inc Regulation des zellwachstums durch muc1
JPWO2002062781A1 (ja) * 2001-02-02 2004-06-10 メルシャン株式会社 イソクマリン誘導体の製造及びそのための合成中間体
US6664401B2 (en) 2001-07-06 2003-12-16 Ilex Products, Inc. Process for preparing isocoumarins
AU2003245935A1 (en) * 2002-06-13 2003-12-31 Novuspharma S.P.A. Derivatives of chromen-2-one as inhibitors of vegf production in mammalian cells
WO2004092339A2 (en) * 2003-04-11 2004-10-28 Ilex Products, Inc. Modulation of muc1 mediated signal transduction
WO2005042573A1 (en) 2003-10-24 2005-05-12 Dana-Farber Cancer Institute, Inc. Modulation of the interaction of muc1 with muc1 ligands
US7683172B2 (en) 2003-11-11 2010-03-23 Eisai R&D Management Co., Ltd. Urea derivative and process for preparing the same
JP2007523214A (ja) * 2004-02-23 2007-08-16 ジェンザイム コーポレイション デスレセプターリガンド誘導アポトーシスのｍｕｃ１アンタゴニスト増強方法
ATE428421T1 (de) 2004-09-17 2009-05-15 Eisai R&D Man Co Ltd Medizinische zusammensetzung mit verbesserter stabilität und reduzierten gelierungseigenschaften
JP4989476B2 (ja) 2005-08-02 2012-08-01 エーザイ・アール・アンド・ディー・マネジメント株式会社 血管新生阻害物質の効果を検定する方法
CN104706637A (zh) 2006-05-18 2015-06-17 卫材R&D管理有限公司 针对甲状腺癌的抗肿瘤剂
WO2008026748A1 (en) 2006-08-28 2008-03-06 Eisai R & D Management Co., Ltd. Antitumor agent for undifferentiated gastric cancer
CA2676796C (en) 2007-01-29 2016-02-23 Eisai R & D Management Co., Ltd. Composition for treatment of undifferentiated gastric cancer
US7972870B2 (en) 2007-02-02 2011-07-05 Dana-Farber Cancer Institute, Inc. Methods and compositions relating to the regulation of MUC1 by HSF1 and STAT3
WO2008097844A2 (en) * 2007-02-02 2008-08-14 Dana -Farber Cancer Institute, Inc. Methods and compositions relating to the regulation of apoptosis by muc1 and bh3- containing proapoptotic proteins
US8952035B2 (en) 2007-11-09 2015-02-10 Eisai R&D Management Co., Ltd. Combination of anti-angiogenic substance and anti-tumor platinum complex
MY162940A (en) 2009-08-19 2017-07-31 Eisai R&D Man Co Ltd Quinoline derivative-containing pharmaceutical composition
CN102958523B (zh) 2010-06-25 2014-11-19 卫材R&D管理有限公司 使用具有激酶抑制作用的组合的抗肿瘤剂
CN103402519B (zh) 2011-04-18 2015-11-25 卫材R&D管理有限公司 肿瘤治疗剂
JP6038128B2 (ja) 2011-06-03 2016-12-07 エーザイ・アール・アンド・ディー・マネジメント株式会社 レンバチニブ化合物に対する甲状腺癌対象及び腎臓癌対象の反応性を予測及び評価するためのバイオマーカー
KR20150098605A (ko) 2012-12-21 2015-08-28 에자이 알앤드디 매니지먼트 가부시키가이샤 퀴놀린 유도체의 비정질 형태 및 그의 제조방법
NZ714049A (en) 2013-05-14 2020-05-29 Eisai R&D Man Co Ltd Biomarkers for predicting and assessing responsiveness of endometrial cancer subjects to lenvatinib compounds
PT3524595T (pt) 2014-08-28 2022-09-19 Eisai R&D Man Co Ltd Derivado de quinolina altamente puro e método para produção do mesmo
LT3263106T (lt) 2015-02-25 2024-01-10 Eisai R&D Management Co., Ltd. Chinolino darinių kartumo sumažinimo būdas
KR102662228B1 (ko) 2015-03-04 2024-05-02 머크 샤프 앤드 돔 코포레이션 암을 치료하기 위한 pd-1 길항제 및 vegfr/fgfr/ret 티로신 키나제 억제제의 조합
MX373231B (es) 2015-06-16 2020-05-08 Eisai R&D Man Co Ltd Agente anticancerigeno.
US12220398B2 (en) 2015-08-20 2025-02-11 Eisai R&D Management Co., Ltd. Tumor therapeutic agent
US12303505B2 (en) 2017-02-08 2025-05-20 Eisai R&D Management Co., Ltd. Tumor-treating pharmaceutical composition
RU2019134940A (ru) 2017-05-16 2021-06-16 Эйсай Ар Энд Ди Менеджмент Ко., Лтд. Лечение гепатоцеллюлярной карциномы

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2802097B2 (ja) * 1989-05-31 1998-09-21 財団法人微生物化学研究会 新規な制癌抗生物質ｍｉ４３―３７ｆ１１及びその製造法
JP3041022B2 (ja) * 1990-08-31 2000-05-15 メルシャン株式会社 抗性物質ｍ１４３―３７ｆ１１の製造方法及び製造中間体
JPH0597841A (ja) * 1991-10-04 1993-04-20 Mercian Corp イソクマリン誘導体
JP3233709B2 (ja) * 1992-12-18 2001-11-26 メルシャン株式会社 免疫調節剤

Also Published As

Publication number Publication date
ES2190469T3 (es) 2003-08-01
CA2259621C (en) 2007-09-18
EP0930310A1 (de) 1999-07-21
US6020363A (en) 2000-02-01
AU6017296A (en) 1998-01-07
EP0930310B1 (de) 2003-03-26
EP0930310A4 (de) 2001-08-22
WO1997048693A1 (en) 1997-12-24
JP3150709B2 (ja) 2001-03-26
JPH08176138A (ja) 1996-07-09
DE69627042T2 (de) 2003-11-20
DE69627042D1 (de) 2003-04-30
CA2259621A1 (en) 1997-12-24

Similar Documents

Publication Publication Date Title
DE69627042D1 (de) Isocumarinderivate und deren verwendung in medikamenten
ATE175669T1 (de) Sulfonylaminopyrimidine, ihre herstellung und verwendung als heilmittel
ATE494009T1 (de) Prodrugs, ihre herstellung und verwendung als arzneimittel
FI943142A0 (fi) Amidi- ja ureajohdannaiset, joilla on veren korkeita kolesteroliarvoja vastustava vaikutus, niiden valmistus ja terapeuttiset käytöt
ATE142630T1 (de) Triazin-derivate und unkrautvertilgungsmittel daraus
DE69418243D1 (de) N-Heteroaryl-N'-Phenylharnstoffderivate, ihre Herstellung und Verwendung
ATE143935T1 (de) Arylcycloalkylderivate, deren herstellung und verwendung
ATE146186T1 (de) Trifluormethylketon peptid derivate mit hle- inhibierende aktivität, deren herstellung und pharmazeutischen zusammensetzungen
ATE94869T1 (de) Diphenylheteroalkylderivate, ihre herstellung und daraus hergestellte arzneimittel und kosmetika.
NO179834C (no) Substituerte cykloheksanderivater og anvendelse av forbindelsene for fremstilling av legemidler
ATE212860T1 (de) Eine neuartige medizinische verwendung eines 5ht 3-antagonisten
DE69305276D1 (de) Arylglycinamidderivate, Verfahren zur deren Herstellung und deren Verwendung zur Therapie der Dysurie
ATE131817T1 (de) 2,4-pyrimidindionderivate und diese enthaltende arzneimittel
BR9611871B1 (pt) diaminopirimidinas, compostos intermediários para a sìntese das mesmas, bem como medicamento que as contém.
ATE141605T1 (de) Thienotriazoldiazepinverbindungen und deren pharmazeutische anwendungen
DE69116237D1 (de) Derivate von Hexahydroazepine, Verfahren zu ihrer Herstellung und diese enthaltende Arzneimittel
ATE114154T1 (de) Thienotriazolodiazepine und ihre pharmazeutische verwendung.
ATE139523T1 (de) Neue verbindungen und deren medizinale verwendung
DE69130266D1 (de) Optisch wirksame Alkylendioxybenzolderivate und ihre Verwendung als Arzneimittel
ATE184282T1 (de) Cyclopropan-derivate und diese enthaltende antivirale mittel
DE3862660D1 (de) 2,3-dihydro-2-oxo-3-benzofuranyl-essigsaeurederivate und diese enthaltende arzneimittel.
ATE140922T1 (de) 3- oder 4-glykosyloxybenzopyranderivat und dieses enthaltende antiallergisches mittel
DE3675758D1 (de) 5-aminoalkyl-beta-carbolinderivate, ihre herstellung und verwendung als arzneimittel.
DE69218205D1 (de) 1,2,4-THIADIAZINO[3,4-b]BENZOTHIAZOL-DERIVATE, IHRE HERSTELLUNG UND SIE ENTHALTENDE ARZNEIMITTEL
IT1241927B (it) 3'-deamino-4'-deossi-4'-amino-8-fluoroantra- cicline processi per la loro preparazione e composizioni farmaceutiche che le contengono

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties